A Functional Polymorphism in a STAT5B Site of the Human PPARγ3 Gene Promoter Affects Height and Lipid Metabolism in a French Population

Aline Meirhaeghe, Lluis Fajas, Fabrice Gouilleux, Dominique Cottel, Nicole Helbecque, Johan Auwerx, Philippe Amouyel

Objective—The peroxisome proliferator-activated receptor-γ (PPARγ) plays a role in adipocyte differentiation and insulin sensitization. It has been shown that genetic variation in the PPARγ gene alters body weight control, lipid and insulin homeostasis, and the susceptibility to type 2 diabetes. Four PPARγ isoforms are generated by alternative splicing and promoter usage. PPARγ3 is only expressed in adipose tissue, colon, and macrophages and therefore seems to be a good candidate gene for metabolic and cardiovascular-associated diseases. In the present study, we looked for genetic variation in the PPARγ3 promoter.

Methods and Results—The proximal PPARγ3 promoter was sequenced in 20 individuals. We detected a C/G polymorphism at position −681 from exon A2. Interestingly, it was located in a signal transducer and activator of transcription 5B (STAT5B) binding consensus site. In a French population (n = 836), the −681G allele was associated with increased height and plasma low-density lipoprotein cholesterol concentrations. In vitro, we showed that the −681G allele completely abolished the binding of STAT5B to the cognate promoter element as well as the transactivation of the PPARγ3 promoter by the growth hormone/STAT5B pathway.

Conclusions—Our results suggest that PPARγ3 may regulate the control of height and lipid homeostasis via the STAT5B pathway. (Arterioscler Thromb Vasc Biol. 2003;23:1469–1475.)

Key Words: obesity ■ cholesterol ■ PPAR ■ growth hormone ■ STAT

Peroxisome proliferator-activated receptor γ (PPARγ) belongs to the nuclear hormone receptor superfamily and heterodimerises with retinoid X receptor (RXR) to regulate target genes involved in adipocyte differentiation and insulin sensitization. PPARγ is activated by several fatty acid derivatives, such as 15-deoxy-Δ12,14-prostaglandin J2, 9- and 13-HODE, and linoleic acid. Furthermore, PPARγ is the receptor that mediates the antidiabetic effects of thiazolidinediones, the oral agents used in the treatment of type II diabetes.8

PPARγ is implicated in several processes, such as adipose,9,10 macrophage,11 and breast12 and colon cell differentiation,13 as well as in glucose and lipid homeostasis.14 The PPARγ gene produces 4 different PPARγ mRNAs by alternative splicing and promoter usage,15–19 giving rise to 2 different proteins, with PPARγ1, PPARγ3, and PPARγ4 being similar and PPARγ2 having an additional 30 amino acids at the N terminus.18 PPARγ1 is ubiquitously expressed, PPARγ2 is restricted to adipose tissue, and PPARγ3 seems mainly confined to macrophages, adipose tissue, and colon.16 The tissue distribution of PPARγ4 has not been explored yet.19 Based on this tissue distribution pattern, PPARγ3 is an interesting candidate gene for genetic susceptibility to metabolic disorders and associated cardiovascular diseases. Mutations in the PPARγ gene have been of great interest in helping to study and unravel the complex and multiple biological actions of PPARγ in vivo. The following mutations in the PPARγ gene have been described: (1) a silent C/T polymorphism in exon 6 associated with higher plasma leptin levels in obese subjects;20 (2) a Pro12Ala substitution in PPARγ2 associated with lower PPARγ2 activity in vitro and decreased type II diabetes risk;21 (3) a very rare Pro15Gln mutation that renders the protein constitutively active associated with a severe obesity phenotype;22 and (4) heterozygous mutations in the ligand-binding domain associated with severe insulin resistance.23 To address the possibility that sequence variations in the promoter of PPARγ3 might be associated with altered expression regulation of PPARγ3, we sequenced the exon A2 and the PPARγ3 promoter in 20 subjects coming from the Northern France MONICA population study.

Methods

The Methods section is available online at http://atvb.ahajournals.org.

Received August 12, 2002; accepted November 12, 2002.

From the Service d’Épidémiologie et de Santé Publique (A.M., D.C., N.H., P.A.), Institut Pasteur de Lille; IGBMC (L.F., J.A.), Illkirch; Faculté de Médecine (F.G.), CHU d’Amiens, Amiens Cedex; and Centre Hospitalier et Universitaire de Lille (P.A.), Lille, France.

Correspondence to Pr. Philippe Amouyel, Service d’Épidémiologie et de Santé Publique, INSERM U.508, Institut Pasteur de Lille, 1 rue Calmette, BP 245, 59019 Lille Cedex, France. E-mail Philippe.Amouyel@pasteur-lille.fr

© 2002 American Heart Association, Inc.

Arterioscler Thromb Vasc Biol is available at http://www.atvbaha.org

DOI: 10.1161/01.ATV.0000051382.28752.FE
Results

A fragment of 851 bp (777 bp of the PPARγ3 promoter and 74 bp of the exon A2) (Figure 1) was sequenced in 20 French subjects. Two polymorphisms were detected: a T/C polymorphism at position −553 and a C/G substitution at position −681 from the beginning of exon A2 (GenBank accession No. AF548352). These two polymorphisms were in complete linkage disequilibrium, but only the C-681G polymorphism was located in the sequence motif TTCATGGAA (polymorphism underlined) that closely resembles the γ-interferon–activated sequence (GAS)-like element (GLE) TTC-NNNGAA. This element has been demonstrated to be a DNA-binding site for transcription factors of the signal transducer and activator of transcription (STAT) family.24,25 A polymorphism in this motif might therefore have a functional impact. Consequently, we decided to analyze the C-681G polymorphism in our French population. The genotype distribution of the PPARγ3 C-681G polymorphism (n=836) was as follows: CC, 56.6%; CG, 36.9%; and GG, 6.5% (G allele frequency, 0.25) (Table 1). This distribution was in Hardy-Weinberg equilibrium. No differences were observed between genders. These frequencies were similar in subjects with type II diabetes (n=49) or with obesity (n=232) (subjects defined with a body mass index [BMI] ≥30 kg/m²) (data not shown). We explored the potential relationship between the PPARγ3 C-681G polymorphism and obesity markers such as body weight, body mass index, plasma leptin levels, and plasma glucose and lipid-related variables. Subjects carrying the −681 G allele were taller and had higher body weight, plasma total and low-density lipoprotein (LDL)-cholesterol, and apolipoprotein B concentrations than CC subjects (Table 2). Because medication during adulthood would not have an effect on height, the impact of the polymorphism on height was also analyzed in the entire population (n=1133), and similar results were found (data not shown). No association with body mass index, waist to hip ratio, or plasma leptin levels could be detected. These results were consistent in both sexes (data not shown).

The C-681G polymorphism is located in a putative STAT binding site. The members of the STAT family are latent cytoplasmic transcription factors that after being tyrosine-phosphorylated in response to various hormones and cytokines (eg, prolactin, growth hormone, interferon γ, and tumor necrosis factor [TNF]-α) translocate to the nucleus, where they regulate the transcription of target genes. We first evaluated the ability of STAT3, STAT5A, and STAT5B to transactivate the PPARγ3 promoter. We created a vector containing the PPARγ3 promoter with the C allele in front of the luciferase gene (pGL3γ3/C). This reporter vector was cotransfected in mouse preadipocyte 3T3-L1 cells together with expression vectors encoding the growth hormone receptor (GHR) and either STAT3, or STAT5A or STAT5B. Cells were incubated in the absence or presence of human growth hormone (hGH), an activator of the STAT proteins. Cells cotransfected with activated STAT5B showed a 3-fold induction of PPARγ3 promoter activity compared with nonactivated STAT5B transfected cells (Figure 2A). Neither activated STAT5A nor activated STAT3 had an effect on the activity of the PPARγ3 promoter (Figure 2A), suggesting that the expression of PPARγ3 seems specifically regulated by STAT5B. To confirm that the activity of the PPARγ3

| TABLE 1. Genotype and Allele Frequencies of the PPARγ3 C-681G Polymorphism |
|-----------------|-----------------|-----------------|
| Genotype        | Allele          |                 |
|                 | CC   | CG   | GG   | C   | G   |
| All             | 836  | 473  | 309  | 54  | 1255| 417  |
| Men             | 419  | 229  | 164  | 26  | 622 | 216  |
| Women           | 417  | 244  | 145  | 28  | 633 | 201  |

Data are n (%) for genotypes and n (frequency) for alleles.
promoter was specific of STAT5B, a vector expressing the transactivation domain-truncated version of STAT5B (STAT5B Δ STAT5B), that acts as a dominant negative toward the full-length STAT5B, which was cotransfected with the PPARγ3-luciferase reporter construct and cells were stimulated by hGH. No induction of the PPARγ3 promoter activity could be detected with the dominant-negative STAT5B vector (Figure 2B). This experiment showed that the PPARγ3 transactivation was specific of STAT5B and that the transactivation domain of STAT5B was necessary to mediate this effect.

To explore whether the PPARγ3 C-681G polymorphism had any influence on the regulation of the PPARγ3 promoter by STAT5B, we made a PPARγ3-luciferase reporter vector including the G allele (pGL33G). 3T3-L1 cells cotransfected with either the pGL33G or pGL33C vector and with expression vectors encoding GHR and STAT5B were incubated in the absence or presence of hGH. Cells stimulated with hGH transfected with pGL33G showed lower PPARγ3 promoter activity than cells transfected with pGL33C at levels comparable to the empty pGL3 vector (Figure 2C).

To additionally investigate the specific transactivation of the PPARγ3 promoter by STAT5B, we evaluated the ability of STAT5A and STAT5B to bind to the PPARγ3 promoter. Nuclear extracts from COS7 cells cotransfected with either STAT5A or STAT5B and GHR expression vectors, stimulated with hGH or not, were prepared and used for electrophoretic mobility shift assays (Figure 3). Radiolabeled 20-mer oligonucleotides containing either the PPARγ3 STAT C or G allele were used as probes. We used the high-affinity STAT binding site from the β-casein gene promoter as a positive control. As expected, no bandshift was detected with nuclear extracts from cells unstimulated with hGH, consistent with the presence of nonactive STAT proteins (lanes 1, 3, 5, 7, 9, and 11). When nuclear extracts from hGH-treated cells transfected with STAT5B were used, a binding to the STAT site containing the C allele could be observed (lane 4). Similar protein-DNA complex was observed when the STAT-binding site of the β-casein was used as a positive probe, suggesting that this DNA-protein complex probably contains the STAT5 protein (lanes 10 and 12). Conversely, STAT5A did not bind to the C allele–containing STAT site (lane 2). When the oligonucleotide containing the G allele was used as a probe with nuclear extracts from cells transfected with activated STAT5B, no binding could be observed (lane 8).

**Discussion**

Taken together, our results suggest that a biallelic polymorphism in the transcriptional regulatory region of PPARγ3 influences height and lipid homeostasis in humans, maybe through the modulation of the PPARγ3 gene transcription by the STAT5B pathway.

We demonstrated that the GH/STAT5B pathway could activate the PPARγ3 promoter in 3T3-L1 cells and that the PPARγ3 C-681G polymorphism prevented it. Furthermore, STAT5B was able to bind the PPARγ3 STAT consensus site, whereas STAT5A was not. STAT5A and STAT5B proteins are products of two different genes and show an ∼90% amino acid similarity. STAT5A and STAT5B have both the abilities of binding the prolactin response element of the β-casein gene and of being activated by GH. However, they differ most markedly in their DNA-binding specificity, which may explain the specific PPARγ3 transactivation by STAT5B only. We also showed that the C-681G allelic variation completely abolished the binding of STAT5B to the PPARγ3 promoter, which could explain the lower activity of the mutant PPARγ3 promoter. We are not excluding the fact that other components than GH such as prolactin, interleukins, erythropoietin, or TNF-α can also activate the STATs.

**TABLE 2. Influence of the PPARγ3 C-681G Polymorphism on Anthropometric and Biological Variables**

<table>
<thead>
<tr>
<th>Genotype</th>
<th>CC (n=473)</th>
<th>CG (n=309)</th>
<th>GG (n=54)</th>
<th>P (3 classes) (CC vs CG+GG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height, cm</td>
<td>166.9±9.4</td>
<td>168.4±9.3</td>
<td>168.1±8.8</td>
<td>0.08</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>71.2±14.5</td>
<td>73.6±14.8</td>
<td>74.5±15.3</td>
<td>0.02</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.5±4.5</td>
<td>25.8±4.4</td>
<td>26.2±4.2</td>
<td>NS</td>
</tr>
<tr>
<td>Waist, cm</td>
<td>87.9±13.0</td>
<td>88.8±12.8</td>
<td>90.0±11.9</td>
<td>NS</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.87±0.09</td>
<td>0.87±0.09</td>
<td>0.87±0.08</td>
<td>NS</td>
</tr>
<tr>
<td>Biological variables</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptin, ng/mL</td>
<td>10.3 (4.0–26.3)</td>
<td>10.2 (4.2–24.5)</td>
<td>11.2 (4.4–28.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>5.74±1.03</td>
<td>5.95±1.07</td>
<td>6.07±1.05</td>
<td>0.01</td>
</tr>
<tr>
<td>LDL cholesterol, mmol/L</td>
<td>3.62±0.99</td>
<td>3.87±1.06</td>
<td>3.96±0.98</td>
<td>0.004</td>
</tr>
<tr>
<td>Apolipoprotein B, g/L</td>
<td>1.15±0.28</td>
<td>1.22±0.31</td>
<td>1.23±0.27</td>
<td>0.009</td>
</tr>
<tr>
<td>HDL cholesterol, mmol/L</td>
<td>1.54±0.48</td>
<td>1.50±0.47</td>
<td>1.56±0.52</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides, mmol/L</td>
<td>1.07 (0.62–1.84)</td>
<td>1.15 (0.62–2.12)</td>
<td>1.04 (0.62–1.73)</td>
<td>NS</td>
</tr>
<tr>
<td>Insulin, μU/mL</td>
<td>12.4 (7.2–21.3)</td>
<td>12.8 (7.8–21.1)</td>
<td>12.2 (7.5–19.7)</td>
<td>NS</td>
</tr>
<tr>
<td>Glucose, mmol/L</td>
<td>5.15 (4.53–5.87)</td>
<td>5.21 (4.53–5.99)</td>
<td>5.37 (4.66–6.17)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Data are means±SD. *P values were adjusted for age, sex, insulin levels, and alcohol and cigarette consumptions. †P values were adjusted for age, sex, BMI, and alcohol and cigarette consumptions.
and modulate PPARγ3 expression. Indeed, it has been shown previously that TPA stimulates PPARγ3 expression in macrophages or that prolactin enhances PPARγ expression in NIH-3T3 cells. Similarly, a STAT1 binding site has been described in the PPARγ2 promoter, and IFN-γ could decrease the promoter activity by acting through this STAT1 site. Therefore, the STAT proteins might have an important role in PPARγ expression regulation.

The higher height in G allele bearers suggests that PPARγ might be implicated in the growth of the skeleton. Several studies have now shown a role for PPARγ in osteoblast/osteoclast activity. It has been shown that low doses of PPARγ ligands induce the osteoblastic maturation of mouse preosteoblast cells, even though high doses inhibit it. Lecka-Czernik and colleagues demonstrated that activation of PPARγ2 with rosiglitazone in U-33/Y2 cells stimulated the differentiation of the cells into adipocytes and blocked their ability to become osteoblasts. The activation of the PPARγ pathway also inhibits the osteoclast formation and activation. Moreover, Ogawa et al reported that primary osteoblasts express PPARγ and that the common PPARγ C/T exon 6 polymorphism is associated with lower bone mineral density in Japanese postmenopausal women. Our results additionally support a potential role for PPARγ in bone metabolism. Growth hormone (GH) is the key hormone of bone metabolism. Its effects are mediated through activation of the GHR, the receptor-associated tyrosine kinase JAK2, and the STATs. PPARγ may modulate some of the effects of GH. A potential modulatory effect of PPARγ over the STAT signaling pathway is suggested by Ricote et al, who showed that the natural or synthetic PPARγ ligands can inhibit STAT activity in a PPARγ-dependent manner. Therefore, PPARγ could attenuate STAT signaling and potentially interfere with GH effects. As a consequence of the C-681G
polymorphism, the expression of PPARγ would be decreased in response to GH, and if we assume that PPARγ inhibits STAT5B, which is a GH mediator, then a mutation in the STAT site is equivalent to increased levels of GH, resulting in a possible increase in final height and body weight of subjects bearing the C allele. The height and body weight of subjects with the C allele were at the upper quartile of the total population, which is an increased fat mass.

Moreover, subjects carrying the G allele had increased plasma apolipoprotein B and total and LDL-cholesterol levels, important cardiovascular risk factors. Monocytes and macrophages, where PPARγ is expressed, are pivotal to the development of atherosclerosis. Ricote et al. showed that PPARγ inhibits the expression of inducible nitric oxide synthase, gelatinase B, and the scavenger receptor A genes in macrophages, probably by antagonizing the transcription factors AT-1, STAT, and nuclear factor-κB. Moreover, our results can also be connected to the fact that PPARγ is an important regulator of the scavenger receptor CD36, a receptor that is thought to be important during macrophage uptake of modified LDL and foam cell formation.

Expression of STAT5A and STAT5B are elevated in murine and human adipocytes compared with their fibroblast precursors. Moreover, the induction of these proteins is regulated in a PPARγ ligand-dependent manner during adipogenesis. The fact that STAT5B knockout mice display elevated plasma GH, abnormal growth rate, and impaired adipocyte differentiation (no lipids in the cells) reinforces the involvement of STAT5B as a mediator of GH and as a factor important in adipocyte differentiation. Therefore, the STAT proteins may regulate fat-specific gene expression as well as upstream transcriptional factors like PPARγ and be themselves regulated by those transcriptional factors.

In conclusion, our data suggest that PPARγ3 may be involved in the control of height and lipid homeostasis in humans through the GH/STAT5B pathway and may mediate some of the proatherogenic effects of GH.

Acknowledgments
ARC, Fondation De France, and Ligand Pharmaceuticals supported this work. The WHO-MONICA population study developed in the North of France was supported by grants from the Conseil Régional "du Nord-Pas de Calais, the Fondation pour la Recherche Médicale, ONIVINS, the Parke-Davis Laboratory, the Mutuelle Générale de l’Education Nationale (MGEN), the Réseau National de Santé Publique, the Direction Générale de La Santé, the Institut National de la Santé Et de la Recherche Médicale (INSERM), the Institut Pasteur de Lille and the Unité d’Evaluation du Center Hospitalier et Universitaire de Lille. Antonio Vidal-Puig and Giles S.H. Yeo are acknowledged for the lecture of the manuscript and helpful comments. Odile Vidal is acknowledged for technical assistance.

References
A Functional Polymorphism in a STAT5B Site of the Human PPARγ3 Gene Promoter Affects Height and Lipid Metabolism in a French Population
Aline Meirhaeghe, Lluis Fajas, Fabrice Gouilleux, Dominique Cottel, Nicole Helbecque, Johan Auwerx and Philippe Amouyel

Arterioscler Thromb Vasc Biol. published online December 12, 2002;
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/early/2002/12/12/01.ATV.0000051382.28752.FE.citation

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2003/02/17/23.2.289.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/